With the development of immunotherapy, the treatment of lung cancer has changed from the use of cytotoxic therapy to a serial of targeted therapies or immunotherapies, such as immune checkpoint blockers like monoclonal antibody-based drugs targeting programmed cell death protein-1 (PD-1) or programmed death ligand-1 (PD-L1). This evidence concerns the gene PDCD1 and lung cancer.